Adipose-derived MSC clusters (S.Biomedics) vs BGC101

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: No discrete molecular target · full Atherosclerotic Cardiovascular Disease pipeline

Adipose-derived MSC clusters (S.Biomedics)

Developed by S.Biomedics

Phase 1/2 in Atherosclerotic Cardiovascular Diseasecell therapy (allogeneic adipose-derived MSC)
Weak signal

NCT04661644 · Phase 1/2 · completed

This was a single-center, open-label study with no control arm. It treated 20 patients with critical limb ischemia in two sequential dose groups and compared each patient with their own baseline. Ischemic pain scores and pain-free walking distance improved over 24 weeks, while ankle-brachial and toe-brachial index did not change, and only one patient had an ulcer. Because there was no comparator group, there was no formal test against a control, so the result is shown as not applicable. The figures come from the peer-reviewed paper in the International Journal of Stem Cells (2025).

Reported efficacy

Changes in ischemic pain (The degrees of changes in VAS measurement on week 4, week 12, week 24, compared to the baseline.); Changes in pain-free walking distance (The degrees of changes in pain-free walking distance on week 4, week 12, week 24, compared to the baseline.); Changes in TBI (Toe Brachial Index) (The degrees of changes in TBI on week 4, week 12, week 24, compared to the baseline.); Changes in ABI (Ankle Brachial Index) (The degrees of changes in ABI on week 4, week 12, week 24, compared to the baseline.); Change in size of the Ulcer (The degrees of changes in Ulcer size on week 4, week 12, week 24, compared to the baseline.); Determination of maximum tolerable dose according to DLT occurrence (Occurrence of ADR is monitored throughout the baseline to week 4 during phase 1.); Incidence of abnormal laboratory tests results (Laboratory tests are performed on screening(-4~-2 week), baseline, 1 day after the baseline, and on week 4, week 12, week 24, compared to the baseline.); Incidence of abnormal blood pressure (Blood pressure is measured throughout the study (on screening visit(4~2 week before the baseline), base line, a day after the baseline, week 4, 12, 24 compared to the baseline.)); Incidence of abnormal temperature (Temperature is measured throughout the study (on screening visit(4~2 week before the baseline), base line, a day after the baseline, week 4, 12, 24 compared to the baseline.)); Incidence of abnormal physical condition (Examined on every visits, throughout the study (on screening visit(4~2 week before the baseline), base line, a day after the baseline, week 4, 12, 24 compared to the baseline.)): Single-arm study, changes from baseline only (no control group). Ischemic pain VAS (all subjects): 51.00±19.59 mm at baseline to 4.60±7.62 mm at week 24, significant decrease vs baseline at weeks 4, 12 and 24 (p<0.05). Pain-free walking distance: significant increase vs baseline, notably at week 12. ABI and TBI: no significant change vs baseline. Ulcer size: only 1 of 20 patients had an ulcer (130 to 49 mm2 at week 24). (not_applicable)

Result source: NCT04661644

BGC101

Developed by BioGenCell

Phase 1/2 in Atherosclerotic Cardiovascular Diseasecell therapy (autologous endothelial progenitor cells)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAdipose-derived MSC clusters (S.Biomedics)BGC101
LDL-C, % change—Not reported—Not reported
Non-HDL-C, % change—Not reported—Not reported
ApoB, % change—Not reported—Not reported
Lp(a), % change—Not reported—Not reported
3-point MACE (% with event)—Not reported—Not reported

LDL-C, % change

Adipose-derived MSC clusters (S.Biomedics)
—Not reported
BGC101
—Not reported

Non-HDL-C, % change

Adipose-derived MSC clusters (S.Biomedics)
—Not reported
BGC101
—Not reported

ApoB, % change

Adipose-derived MSC clusters (S.Biomedics)
—Not reported
BGC101
—Not reported

Lp(a), % change

Adipose-derived MSC clusters (S.Biomedics)
—Not reported
BGC101
—Not reported

3-point MACE (% with event)

Adipose-derived MSC clusters (S.Biomedics)
—Not reported
BGC101
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

BGC101: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Adipose-derived MSC clusters (S.Biomedics)
Single-arm study, changes from baseline only (no control group). Ischemic pain VAS (all subjects): 51.00±19.59 mm at baseline to 4.60±7.62 mm at week 24, significant decrease vs baseline at weeks 4, 12 and 24 (p<0.05). Pain-free walking distance: significant increase vs baseline, notably at week 12. ABI and TBI: no significant change vs baseline. Ulcer size: only 1 of 20 patients had an ulcer (130 to 49 mm2 at week 24). NCT04661644 · Phase 1/2 · design grade: weak · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Adipose-derived MSC clusters (S.Biomedics)'s landscape · BGC101's landscape